Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Nov 9;12(1):1732852.
doi: 10.1080/19490976.2020.1732852. Epub 2020 Mar 13.

Oral delivery of Hyperimmune bovine serum antibodies against CS6-expressing enterotoxigenic Escherichia coli as a prophylactic against diarrhea

K R Talaat  1 , C K Porter  2 , A L Bourgeois  1 , T K Lee  2 , C A Duplessis  2 , M Maciel Jr  3 , R L Gutierrez  2 , B DeNearing  1 , B Adjoodani  1 , R Adkinson  1 , K J Testa  3 , B Feijoo  1 , A N Alcala  3 , J Brubaker  1 , A Beselman  1 , S Chakraborty  1 , D Sack  1 , J Halpern  1 , S Trop  3 , H Wu  4 , J Jiao  4 , E Sullivan  4 , M S Riddle  2 , S S Joseph  3 , S T Poole  3 , M G Prouty  2
Affiliations
Randomized Controlled Trial

Oral delivery of Hyperimmune bovine serum antibodies against CS6-expressing enterotoxigenic Escherichia coli as a prophylactic against diarrhea

K R Talaat et al. Gut Microbes. .

Abstract

Background: . Oral administration of bovine antibodies active against enterotoxigenic Escherichia coli (ETEC) have demonstrated safety and efficacy against diarrhea in human challenge trials. The efficacy of bovine serum immunoglobulins (BSIgG) against recombinant colonization factor CS6 or whole cell ETEC strain B7A was assessed against challenge with the CS6-expressing B7A.

Methods: . This was a randomized, double-blind, placebo-controlled trial in which healthy adults received oral hyperimmune BSIgG anti-CS6, anti-B7A whole cell killed or non-hyperimmune BSIgG (placebo) in a 1:1:1 ratio then challenged with ETEC B7A. Two days pre-challenge, volunteers began a thrice daily, seven day course of immunoprophylaxis. On day 3, subjects received 1 × 1010 CFUs of B7A. Subjects were observed for safety and the primary endpoint of moderate-severe diarrhea (MSD).

Results: . A total of 59 volunteers received product and underwent ETEC challenge. The BSIgG products were well-tolerated across all subjects. Upon challenge, 14/20 (70%) placebo recipients developed MSD, compared to 12/19 (63%; p = .74) receiving anti-CS6 BSIgG and 7/20 (35%; p = .06) receiving anti-B7A BSIgG. Immune responses to the ETEC infection were modest across all groups.

Conclusions: . Bovine-derived serum antibodies appear safe and well tolerated. Antibodies derived from cattle immunized with whole cell B7A provided 50% protection against MSD following B7A challenge; however, no protection was observed in subjects receiving serum antibodies targeting CS6. The lack of observed efficacy in this group may be due to low CS6 surface expression on B7A, the high dose challenge inoculum and/or the use of serum derived antibodies versus colostrum-derived antibodies.

Keywords: Enterotoxigenic Escherichia coli; controlled human infection model; diarrhea; passive prophylaxis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Quantitative shedding of ETEC strain B7A on two days after oral challenge.
Figure 2.
Figure 2.
Serologic responses to oral challenge with ETEC strain B7A stratified by treatment group.
See this image and copyright information in PMC

References

    1. Chakraborty S, Harro C, DeNearing B, Ram M, Feller A, Cage A, Bauers N, Bourgeois AL, Walker R, Sack DA, et al. Characterization of mucosal immune responses to Enterotoxigenic Escherichia coli vaccine antigens in a human challenge model: response profiles after primary infection and homologous rechallenge with strain H10407. Clin Vaccine Immunol. 2016;23(1):55–11. doi:10.1128/CVI.00617-15. - DOI - PMC - PubMed
    1. DuPont HL, Formal SB, Hornick RB, Snyder MJ, Libonati JP, Sheahan DG, LaBrec EH, Kalas JP.. Pathogenesis of Escherichia coli diarrhea. N Engl J Med. 1971;285(1):1–9. doi:10.1056/NEJM197107012850101. - DOI - PubMed
    1. Gaastra W, Svennerholm AM. Colonization factors of human enterotoxigenic Escherichia coli (ETEC). Trends Microbiol. 1996;4(11):444–452. doi:10.1016/0966-842X(96)10068-8. - DOI - PubMed
    1. Qadri F, Das SK, Faruque AS, Fuchs GJ, Albert MJ, Sack RB, Svennerholm AM. Prevalence of toxin types and colonization factors in enterotoxigenic Escherichia coli isolated during a 2-year period from diarrheal patients in Bangladesh. J Clin Microbiol. 2000;38:27–31. - PMC - PubMed
    1. Clemens JD, Sack DA, Harris JR, Chakraborty J, Neogy PK, Stanton B, Huda N, Khan MU, Kay BA, Khan MR, et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis. 1988;158(2):372–377. doi:10.1093/infdis/158.2.372. - DOI - PubMed

Publication types

MeSH terms